Nephrocare Health Services Ltd (NEPHROPLUS)

📊 Quarterly Results (₹ Cr)

Revenue growth has accelerated sequentially and YoY, with ₹282 crores in Q1 FY27 marking the third consecutive quarter of double-digit growth, driven by international expansion and volume gains. Operating margins expanded to 14% in Q1 FY27 from 10.5% in Q4 FY26, supported by COGS reduction and scale efficiencies, while PAT margin reached 13.1%, up from breakeven in the prior quarter. The company achieved profitability despite heavy reinvestment, with PAT turning positive after a ₹9 crore loss in Q3 FY25, indicating improving operational resilience and scalability of its asset-light model.

🔮 Management Outlook & What's Next

Management expects sustained growth through international expansion, targeting 10-15 countries within 5-10 years and increasing utilization to 85% across the network. Price increases are planned every 5-10 years, with recent examples including a 35% CGHS hike after over a decade. The company is pursuing strategic acquisitions and long-term partnerships with payors to enter new markets, particularly in regions with strong reimbursement frameworks. Capex remains disciplined at 40-50 Indian and 10-15 Philippine clinics annually, with depreciation declining sequentially despite acquisitions due to improved asset tracking, supporting long-term capital efficiency.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a strong equity base of ₹20 crores with ₹1,096 crores in reserves as of March 2026, indicating robust capitalization and retained earnings growth. Borrowings remain low at ₹23 crores, suggesting minimal financial leverage and a conservative capital structure. Total assets have grown to ₹1,471 crores, up from ₹999 crores a year ago, driven by expansion in clinics and infrastructure, while equity has increased significantly, supporting ongoing reinvestment without dilutive financing.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 63.85%, indicating confidence in long-term prospects, while FII and DII stakes have increased to 8.78% and 9.05% respectively in Q1FY27 from 9.94% and 8.64% in Q4FY26, suggesting institutional accumulation. The number of public shareholders has grown to 44,091 from 43,409, reflecting broader retail interest. However, shareholder count declined slightly in Q3FY26 to 67,416, possibly due to consolidation, but overall ownership structure remains stable with no signs of promoter pledging or significant dilution.

⚖️ Peer Comparison — Healthcare

🔗 Peer Stock Analyses

⚠️ Risk Factors

The company's rapid international expansion exposes it to regulatory, reimbursement, and operational risks in new markets, particularly in countries like Uzbekistan where tax rates are zero but market maturity and scalability are unproven. Margin improvement relies heavily on cost discipline and asset-light execution, which may face pressure as clinic density increases and utilization targets rise to 85%. Currency fluctuations and geopolitical instability in emerging markets could impact profitability, while competitive dynamics in dialysis services may erode pricing power over time. Additionally, the long cycle of price increases (every 5-10 years) limits near-term revenue levers beyond volume and expansion.

📋 Recent Filings

• 🔴 Insider Trading2026-09-28Polar Capital Funds PLC disclosed through its three healthcare-focused funds a 2.535% off-market purchase of 2,549,478 Nephrocare Health Services Ltd …
• Announcement2026-09-25Nephrocare Health Services Ltd announced the closure of its trading window effective October 1, 2026, due to pending unaudited financial results for t…
• 🔴 Announcement2026-09-22Nephrocare Health Services Ltd announced it will attend an investor conference on September 29, 2026 at 1:00 PM IST at Trident BKC, Mumbai, hosted by …
• 🟡 Board Meeting2026-09-18Nephrocare Health Services announced on September 18, 2026, that its board approved the rationalisation and consolidation of its Philippine step-down …
• 🔴 Announcement2026-09-18Nephrocare Health Services announced that India Ratings upgraded its long-term bank loan facilities to IND AA- from IND A+ with a Stable outlook, whil…
• 🔴 Announcement2026-09-14Nephrocare Health Services announced a memorandum of understanding to acquire a Philippine dialysis center through an Asset Transfer Agreement dated S…
• 🟡 Board Meeting2026-09-03Nephrocare Health Services approved the grant of 4,01,362 employee stock options under its 2026 ESOP scheme on September 3, 2026, with an exercise pri…
• 🔴 Corporate Action2026-09-01Nephrocare Health Services announced on September 1, 2026, that its subsidiary NPHSK LLP will acquire 100% of Dialysis Center Almaty LLP in Kazakhstan…
• 🔴 Announcement2026-08-31Nephrocare Health Services disclosed that its Uzbekistan subsidiary received a tax assessment order from the Tashkent City Tax Department dated August…
• 🔴 Financial Results2026-08-19Nephrocare Health Services reported **₹282 crores** revenue in Q1 FY27, up **23.7% YoY**, driven by international expansion (now **45%** of revenue) a…

🧠 Analyst's Read

Nephrocare is executing a clear, capital-efficient internationalization strategy with strong operational momentum, but its valuation reflects high growth expectations that may be difficult to sustain if margin expansion slows or expansion encounters execution risks. Investors should monitor clinic utilization trends, new market entry timelines, and reimbursement policy shifts in target countries as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.